Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APMOTCMKTS:GTHPOTCMKTS:ORTIFOTCMKTS:POLXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.99-4.8%$0.97$0.46▼$7.49$5.56M-0.14619,373 shs49,823 shsGTHPGuided Therapeutics$0.23$0.13$0.06▼$0.23$18.15M-0.113,384 shs361 shsORTIFOrtho Regenerative Technologies$0.20$0.20$0.13▼$0.45$6.86M-1.163,282 shsN/APOLXFPolydex Pharmaceuticals$1.99+0.3%$1.99$0.55▼$2.01N/AN/AN/A2,000 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group-4.81%-13.91%+9.82%+7.61%-78.00%GTHPGuided Therapeutics0.00%+21.05%+84.00%+131.16%+53.33%ORTIFOrtho Regenerative Technologies0.00%0.00%0.00%0.00%0.00%POLXFPolydex Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPMAptorum Group0.4879 of 5 stars0.03.00.00.00.61.70.6GTHPGuided TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AORTIFOrtho Regenerative TechnologiesN/AN/AN/AN/AN/AN/AN/AN/APOLXFPolydex PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 0.00N/AN/AN/AGTHPGuided Therapeutics 0.00N/AN/AN/AORTIFOrtho Regenerative Technologies 0.00N/AN/AN/APOLXFPolydex Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum Group$430K12.32N/AN/A$2.20 per share0.45GTHPGuided Therapeutics$10K1,814.93N/AN/A($0.12) per share-1.92ORTIFOrtho Regenerative TechnologiesN/AN/AN/AN/A($0.16) per shareN/APOLXFPolydex Pharmaceuticals$4.41MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$4.27MN/A0.00∞N/AN/AN/AN/A7/30/2025 (Estimated)GTHPGuided Therapeutics-$2.42M-$0.05N/A∞N/AN/AN/A-197.32%8/12/2025 (Estimated)ORTIFOrtho Regenerative Technologies-$3.93M-$0.11N/AN/AN/AN/AN/A-269.68%N/APOLXFPolydex Pharmaceuticals-$770KN/A0.00∞N/AN/AN/AN/AN/ALatest POLXF, APM, GTHP, and ORTIF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GTHPGuided TherapeuticsN/A-$0.01N/A-$0.01N/AN/A3/31/2025Q4 2024GTHPGuided TherapeuticsN/A-$0.02N/A-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/AGTHPGuided TherapeuticsN/AN/AN/AN/AN/AORTIFOrtho Regenerative TechnologiesN/AN/AN/AN/AN/APOLXFPolydex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.220.22GTHPGuided TherapeuticsN/A0.140.03ORTIFOrtho Regenerative TechnologiesN/A1.261.26POLXFPolydex PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%GTHPGuided Therapeutics9.69%ORTIFOrtho Regenerative TechnologiesN/APOLXFPolydex PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%GTHPGuided Therapeutics66.83%ORTIFOrtho Regenerative TechnologiesN/APOLXFPolydex Pharmaceuticals12.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group305.35 million1.93 millionNot OptionableGTHPGuided Therapeutics578.91 million26.18 millionNot OptionableORTIFOrtho Regenerative TechnologiesN/A34.96 millionN/ANot OptionablePOLXFPolydex Pharmaceuticals20N/AN/ANot OptionablePOLXF, APM, GTHP, and ORTIF HeadlinesRecent News About These CompaniesGoede v. AstraZeneca Pharmaceuticals, LPApril 2, 2024 | scotusblog.comDrug Discovery & PharmaceuticalsOctober 20, 2023 | news-medical.netPolydex Pharmaceuticals Limited Shareholders Vote to Approve BioSpectra Inc. Business CombinationJuly 18, 2023 | finance.yahoo.comPolydex Pharmaceuticals Limited: Polydex Pharmaceuticals Issues First Quarter Financial ResultsJune 15, 2023 | finanznachrichten.dePolydex Pharmaceuticals Limited and BioSpectra Inc. Announce Business CombinationApril 27, 2023 | finance.yahoo.comPolydex Pharmaceuticals Ltd.April 18, 2023 | barrons.comPolydex Pharmaceuticals GAAP EPS of -$0.09, revenue of $1.09MSeptember 17, 2022 | seekingalpha.comGlobal Computed Tomography (CT) Scanner Market to Reach $9.38 Billion by 2028 | Demand for AI based CT Scanner is On the RiseSeptember 16, 2022 | nz.finance.yahoo.comPolydex Pharmaceuticals LtdAugust 24, 2022 | reuters.comPolydex Pharmaceuticals Limited (POLXF)August 13, 2022 | finance.yahoo.comPolydex Pharmaceuticals GAAP EPS of -$0.02, revenue of $1.15MJune 17, 2022 | seekingalpha.comMarshall Plan for Moms Mother's Day Mission: Cure Chronic Mom GuiltMay 4, 2022 | nz.finance.yahoo.comQED Investors Hires Victoria Zuo to Help Scale Early Stage TeamMay 3, 2022 | nz.finance.yahoo.comTaste: Protein shakes are a great tool to meet macro goalsMay 3, 2022 | yahoo.comPolydex Pharmaceuticals Inc (POLXF)January 29, 2022 | nasdaq.comPolydex Pharmaceuticals Announces Collaboration with Termanox Water Treatment Solutions for novel use of Native DextranJanuary 26, 2022 | finance.yahoo.comPolydex Pharmaceuticals Ltd (POLXF)January 5, 2022 | investing.comPolydex Pharmaceuticals Revenue (5 Year Growth)December 21, 2021 | ycharts.comPolydex Pharmaceuticals Year to Date Total Returns (Daily)December 17, 2021 | ycharts.comPolydex Pharmaceuticals EPS Diluted (5 Year Growth)December 17, 2021 | ycharts.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePOLXF, APM, GTHP, and ORTIF Company DescriptionsAptorum Group NASDAQ:APM$0.99 -0.05 (-4.81%) Closing price 06/20/2025 03:47 PM EasternExtended Trading$1.04 +0.05 (+5.56%) As of 06/20/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.Guided Therapeutics OTCMKTS:GTHP$0.23 0.00 (0.00%) As of 06/20/2025 01:28 PM EasternGuided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.Ortho Regenerative Technologies OTCMKTS:ORTIF$0.20 0.00 (0.00%) As of 09/9/2022Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.Polydex Pharmaceuticals OTCMKTS:POLXF$1.99 +0.01 (+0.30%) As of 08/7/2023Polydex Pharmaceuticals Ltd. is a development stage company, which engages in manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry, and the development, manufacturing, and marketing of biotechnology-based products for the human pharmaceutical market. The firm focuses on Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The company was founded by Thomas C. Usher on June 14, 1979 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
